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Association of 1800 cGy cranial irradiation with intellectual
function in children with acute lymphoblastic leukaemia
Summary
Cranial radiation therapy in childhood acute lymphoblastic
leukaemia has been associated with adverse
neuropsychological effects, such as low intelligence. However,
records show that these associations usually occur when the
dose of radiation used is 2400 cGy. We investigated whether a
lower dose of 1800 cGy had the same adverse effects on
long-term survivors and whether high doses of methotrexate
but no radiation therapy would have a more beneficial effect.
We evaluated 203 children for six years in a multi-centre
European study. The patients were divided into two groups:
129 children treated with 1800 cGy of cranial radiation
therapy and 74 children who received high-dose methotrexate
but no radiation therapy. We used full scale intelligence
quotient, verbal, and performance IQ tests to assess the
patient’s intelligence. We found a significant decline in full
scale intelligence quotient in the irradiated group that
increased with the length of time from diagnosis. Younger age
at diagnosis was associated with lower full scale intelligence
quotient in the radiated group.
Our results indicate that a radiation dose of 1800 cGy can
have negative effects on neurocognitive function and we
continue to question the benefit of low-dose cranial radiation
therapy.
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Introduction
Neuropsychological sequelae have been the most
extensively studied late effects in long-term survivors of
childhood acute lymphoblastic leukaemia (ALL). These
late adverse effects follow treatment with preventive central
nervous system (CNS) therapy, which can usually include
2400 cGy of cranial radiation therapy with intrathecal
chemotherapy. Younger children are much more at risk of
developing adverse effects which may only become
apparent several years after CNS treatment.3-8 The severity
of these late effects tends to increase with time since
diagnosis (or time since first treatment).9,10
To minimise the adverse effects of CNS prophylaxis,
subsequent treatment protocols have used lower doses of
cranial radiation therapy (reduced to 1800 cGy) or have
replaced cranial radiation therapy by high-dose
methotrexate. Only a few studies have compared the
possible adverse effects on patients of having 1800 cGy
treatment or no radiation therapy, and such studies
have produced conflicting results. These differences
may be due to small sample sizes or because of short
follow-up.
We evaluated intellectual performance in a large multi-
national group of long-term survivors of childhood ALL
who received preventive therapy of 1800 cGy and children
who received no cranial radiation therapy but who did
receive high doses of methotrexate.
Patients and methods
Patients
We studied 203 children who were in continuous first remission of
ALL. Patients had stopped therapy for at least 18 months and were
aged between 6 and 17. We treated these patients for low or
standard risk ALL in 14 paediatric cancer treatment centres in 5
European countries between 1979 and 1988. Few patients refused
to participate. Patients who had CNS involvement or prior
neurological disease were excluded. The different national
treatment protocols included the same drugs in similar schedule
rotation and dosage: systemic induction chemotherapy (ranging
from 6-10 weeks) with vincristine, steroids, anthracyclines, L-
asparaginase, 6-mercaptopurine, and methotrexate (MTX), was
followed by a consolidation phase that included CNS preventive
therapy.
Our investigation was a retrospective study with a concurrent,
non-random control. We found that 2 groups emerged: those
treated with cranial irradiation, up to 1800 cGy in 10-12 session;
n=129 and intrathecal chemotherapy; mostly intratheral
methotrexate, dosage age dependent for a total of 5 or 6 doses, and
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Table: Patient characteristics
those treated without cranial radiation therapy (n = 74) but with
intravenous high-dose methotrexate (2 to 8 gjm2) for 4 doses plus
intrathecal methotrexate cytarabine and a corticosteroid (triplet,
dosage age dependent) for 14 doses.
The protocols usually included a reinduction phase with the
same drugs. Systemic maintenance therapy with oral or
intramuscular methotrexate plus oral 6-mercaptopurine was
followed-up for 24 months.14,16
The 2 groups were comparable in gender distribution, age at
diagnosis, time since diagnosis, and age at test (table). In this
sample, age at diagnosis and time since diagnosis were negatively
correlated (r=-0.31).
Intelligence
All patients were individually assessed with the most recent
national standardised form of the Wechsler Intelligence Scale for
Children (WISC). We analysed the age-scaled overall summary
measure full scale intelligence quotient (FSIQ) as well as its
component parts, verbal intelligence quotient (VIQ), and
performance intelligence quotient (PIQ).
Statistics
We statistically analysed our study by applying a general linear
model in which the dependent variable FSIQ was related to
therapy (cranial radiation therapy: yes or no), time since diagnosis,
Time since diagnosis (yrs)
Figure 1: Effects of treatment with 1800 cGy cranial radiation
or no radiation therapy on Intellectual performance as a
function of time since diagnosis
V
0-3 3-6 6-12
Age at diagnosis (yrs)
Figure 2: Effects of treatment with 1800 cGy cranial radiation
or no radiation therapy on Intellectual performance as a
function of age at diagnosis
and age at diagnosis. The variables time since and age at diagnosis
were analysed separately and the related slopes were estimated.
When the interaction of type of treatment with time since
diagnosis, or age at diagnosis, was significant, the former effects
were evaluated for the irradiated and non-irradiated groups, and
the related slopes estimated. Analysis of the effects of radiation or
no radiation on intellectual function was done with VIQ, and PIQ.
The distribution of radiated versus non-radiated patients was not




Figure 1 shows two significant effects; time since diagnosis
(F=988, p=0002) and cranial irradiation therapy
(F=5-03, p=0-02). The interaction between time since
diagnosis and treatment was significant (F = 6 00, p = 0-02)
and indicated that the radiated group showed a significant
decline in FSIQ as time since diagnosis became longer (loss
of3-65 [0.83] IQ points per year; p < 0.001). However, in the
non-irradiated group, the association with time since
diagnosis (- 0-45 [1-O1]) was not significant. Similar effects
were seen when we analysed the component parts of the
FSIQ: VIQ (slopes of - 3-67 [0’85] in their radiated group
versus 0-07 [1’04] in the non-irradiated group) and PIQ
(slopes of - 2-76 [0’88] vs - 1.09 [1-07]).
Age at diagnosis
Figure 2 shows the significant effects of age at diagnosis
(F=6-0, p=0-02) and cranial radiation therapy (F=4-7,
p = 0 03), and the interaction between treatment and age at
diagnosis (F=3-81; p=0-05). The radiated patients had
significantly lower FISQ’s as age at diagnosis became
smaller (loss of 1-87 [0.57] IQ points per year; p < 0001),
whereas in the nonirradiated group the slope for age at
diagnosis (0-21 [0’64]) was not significantly different from
zero. Similar effects were seen when we analysed VIQ
(slopes of 1-61 [0’59] vs -0-21 [0’66]) and PIQ (slopes of
1 75 [0-59] vs 0-65 [0-66]).
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Discussion
Our results show that 1800 cGy treatment has negative late
effects on neurocognitive function. There were two major
findings.
A significant decline in FSIQ after lengthening time
from diagnosis was observed only in the irradiated group;
and younger age at diagnosis was associated with lower
levels of FSIQ in the irradiated group. These effects were
also found when analysing VIQ and PIQ separately. The
irradiated group had a significant loss of almost 4 IQ points
per year since diagnosis, whereas the non-irradiated group
did not.
However, we should be cautious when interpreting the
size of this decline outside the scope and range of our study.
Approximately 80% of patients were between 4 and 8-5
years from diagnosis, so extrapolation outside this range
would be an overinterpretation of our data. The main
finding is the decline of intelligence in the irradiated group
and the difference with the non-irradiated group. We also
note that our range of follow-up included the period when
other studies indicate that CNS changes become apparent17
or that declines in IQ occurred, that is 3-7 years after
diagnosis and CNS prophylaxis.8,9,10
Reports of previous research investigating the effects of
1800 cGY cranial radiation therapy are contradictory.
Investigators reported that 1-2 years after cranial radiation
therapy they do not see a decline in intelligence. 12,18,19
However, in a longer follow-up, CRT has been associated
with significant decreases in intellectual functioning and
academic achievement8,11,13,20 or lower neurocognitive
functioning compared with normal.21
In a subsequent report, Mulhern et al22 disagreed
suggesting that decreases in IQ,13,20 which were observed
for both the 1800 cGy group and the non-irradiated group
on high dose methotrexate, were because of a change in the
type of IQ test used. Similarly, Brouwers et al23 reported
there was no decline in IQ after a 3-5 year follow-up. These
inconsistencies can be explained by differences in sample
selection and inclusion or exclusion of patients with CNS
leukaemia or with relapses, but especially by differences in
neuropsychological tests, assessment intervals, and small
sample sizes.
Younger children are at greater risk for late adverse
effects, particularly after a dose of 2400 cGy radiation. Our
findings with 1800 cGy are similar to those with 2400
cGy.1,19,24,25 Younger children at diagnosis were more
affected by radiation therapy than older children, whereas
age at diagnosis did not affect children who did not have
radiation therapy.
CNS preventive therapy for ALL with 2400 cGy and
intrathecal chemotheapy has been associated with late
adverse effects in the form of histopathological, brain
imaging, neuroendocrine, and neuropsychological
abnormalities,26 and with possible secondary
malignancy.27-29 This has led to development of therapy
that would be equally protective but less toxic. One
approach has been to reduce the dose of cranial irradiation
from 2400 to 1800 cGy, and even to 1200 cGy. Our data
indicate that 1800 cGy is still associated with negative late
effects, even if the magnitude is reduced. A re-evaluation of
cranial irradiation in patients not at high risk now seems
warranted.
The advantages of our study are that we used only one IQ
test, follow-up included the time period when late effects
usually become apparent, and the size of our study
population was large compared with previous studies. The
limitations are that the two treatment arms were not
randomised and that this is not a longitudinal study.
However, our two groups were large thus reducing the
contribution of chance fluctuations and baseline
inequalities to the observed effects.3&deg; Moreover, the two
groups were well matched on most variables, particularly
age at diagnosis, time since diagnosis, and age at test.
In conclusion, the results we obtained with our large
sample ALL patients who remained in the study many
years after diagnosis, indicate a debilitating effect of 1800
cGy on intellectual functioning of long-term survivors.
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